Beckman Coulter, Inc. introduced the SPRI-TE Nucleic Acid Extractor for the automated purification of DNA and RNA. This new, easy-to-use system prepares between one and 10 samples in about 30 minutes and requires minimal user training. Prepackaged, ready to use extraction kits are available for preparing genomic DNA, viral or formalin-fixed, paraffin-embedded (FFPE) nucleic acid samples.
SPRI-TE incorporates Beckman Coulter's proprietary SPRI (solid phase reversible immobilization) technology, which extracts the nucleic acids without centrifugation or vacuum manifold. The SPRI technology ensures stronger binding and higher quality purification than silica-coated beads, which can shear nucleic acids, leading to lower quality results.
"As more and more clinical labs add molecular diagnostic tests to their offerings, the need for a small and easy-to-use nucleic acid extractor is growing," commented Bernhard Spiess, vice president of marketing for Beckman Coulter's Molecular Diagnostics Business Center. "Our top performing bead technology is already being applied by industry leaders in diagnostic applications including oncology, infectious disease and inherited disorders"
SPRI-TE customers are supported 24 hours a day, seven days a week by Beckman Coulter's experienced service network, which has a 70-year track record.
BEC Introduces New SPRITE Nucleic Acid Extractor
Beckman Coulter, Inc., based in Orange County, California, develops, manufactures and markets products that simplify, automate and innovate complex biomedical tests. More than 200,000 Beckman Coulter systems operate in laboratories around the world, supplying critical information for improving patient health and reducing the cost of care. Recurring revenue, consisting of supplies, test kits, service and operating-type lease payments, represents approximately 78 percent of the company's 2007 annual revenue of $2.76 billion. For more information, visit http://www.beckmancoulter.com.
SOURCE: Beckman Coulter, Inc.